RAS oncogenes: weaving a tumorigenic web
Open accessThe DOI matches its Crossref record; 243 of the 243 references it cites were found in a registry or an index.
Abstract
RAS proteins are essential components of signalling pathways that emanate from cell surface receptors. Oncogenic activation of these proteins owing to missense mutations is frequently detected in several types of cancer. A wealth of biochemical and genetic studies indicates that RAS proteins control a complex molecular circuitry that consists of a wide array of interconnecting pathways. In this Review, we describe how RAS oncogenes exploit their extensive signalling reach to affect multiple cellular processes that drive tumorigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Obviously, the RAF-MEK-ERK pathway is not the only pathway controlled by KRAS, 18 which is supported by findings demonstrating enhanced efficacy of combining MEK inhibitors with phosphoinositide 3-kinase inhibitors in NSCLC models.19,20”
From K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways (2019) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“Mutations in G12, G13, or Q61 residue in the active site can lock KRAS in the GTP-bound form by impeding the hydrolysis to GDP catalyzed by GAPs, thus keeping downstream signaling constitutively active [16, 17].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [17]
In the citing paper
“PDEδ has a large hydrophobic pocket that can bind farnesyl proteins, especially the lipid portion of KRAS protein, thereby preventing the farnesyl modification of KRAS protein from binding to cell membrane and inhibiting tumor cell proliferation and growth.339,340”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [340]
In the citing paper
“The resulting RAS-mediated signaling cascades drive tumor initiation, maintenance and progression by deregulating key cellular processes, for instance by increasing proliferation and suppressing apoptosis, but also by rewiring cellular metabolism and promoting alterations in the tumor microenvironment3.”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [3]
In the citing paper
“By constitutively activating these pathways, the Ras oncoprotein confers growth, survival and metastatic advantages to the cancer cell (11).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [11]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“To accommodate the emergence of additional cancer-associated pathologies this list has been increased to include additional hallmarks such as metabolic fitness and genomic plasticit”
BackgroundHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425 · cited 1×
“These unique metabolic needs were first described in the 1920s by Otto Warburg and are typified by an increase in glucose uptake and a shift from mitochondrial oxidative phosphorylation to aerobic glycolysi”
BackgroundAkt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Disruption of epithelial cell-matrix interactions induces apoptosis
Frisch, S., & Francis, H. (1994) · The Journal of cell biology · doi:10.1083/jcb.124.4.619 · Cited by 3,254
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797 · cited 1×
“Hence, the modification of the surrounding ECM is necessary both for the growth factors to reach the target endothelium and for the migration of the newly generated endothelium into the tumou”
BackgroundDNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“An inevitable consequence of the persistent mitogenic stimulation that is imposed by RAS is the initiation of replicative stress, which is marked by increased numbers of active DNA replication origins and collapsed replication forks, which ultimately leads to DNA damage and the activation of the DNA damage response (D…”
BackgroundPreinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471
Cited by
Items 501–600 of 1,003
Targeting mutated GTPase KRAS in tumor therapies
Fan, G., Lou, L., Song, Z., Zhang, X., & Xiong, X. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113816 · Cited by 48
The role of T-cells in head and neck squamous cell carcinoma: From immunity to immunotherapy
Damasio, M. P. S., Nascimento, C. S., de Andrade, L. M., de Oliveira, V. L., & Calzavara-Silva, C. E. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1021609 · Cited by 48
Zhou, C., Fan, Z., Gu, Y., Ge, Z., Tao, Z., Cui, R., Li, Y., Zhou, G., Huo, R., Gao, M., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01622 · Cited by 45
From Concepts to Inhibitors: A Blueprint for Targeting Protein–Protein Interactions
Hong, S. H., Nguyễn, T. T., Ongkingco, J. F., Nazzaro, A., & Arora, P. S. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00046 · Cited by 46
Alberghina, L., Gaglio, D., Gelfi, C., Moresco, R. M., Mauri, G., Bertolazzi, P., Messa, C., Gilardi, M. C., Chiaradonna, F., & Vanoni, M. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00362 · Cited by 51
“As discussed in a recent review (Pylayeva-Gupta et al., 2011), oncogenic ras activation promotes the stimulation of several signaling pathway (Raf-MAPK, PI3K, Rho-Rac, and Ral-Gef) that converge to activate cyclin D1 synthesis and stabilization, whose increase together with the down-regulation of…”
BackgroundNanomicellar Carriers for Targeted Delivery of Anticancer Agents
Zhang, X., Huang, Y., & Li, S. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.135 · Cited by 47
Chu, P.-C., Yang, M.-C., Kulp, S. K., Salunke, S. B., Himmel, L. E., Fang, C.-S., Jadhav, A. M., Shan, Y.-S., Lee, C. T., Lai, M.-D., et al. (2015) · Oncogene · doi:10.1038/onc.2015.458 · Cited by 50
Oliveira, R. J. D. S., Silva, V. A. O., Martinho, O., Cruvinel‐Carloni, A., Melendez, M. E., Rosa, M. N., de Paula, F. E., Viana, L. D. S., Carvalho, A. L., & Reis, R. M. (2016) · Cellular Oncology · doi:10.1007/s13402-016-0270-z · Cited by 47
Vo, U., Vajpai, N., Flavell, L., Bobby, R., Breeze, A. L., Embrey, K. J., & Golovanov, A. P. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.691238 · Cited by 40
Mosaicism in Cutaneous Disorders
Lim, Y. H., Moscato, Z. M., & Choate, K. A. (2017) · Annual Review of Genetics · doi:10.1146/annurev-genet-121415-121955 · Cited by 48
Mutational analysis ofKRASand its clinical implications in cervical cancer patients
Jiang, W., Xiang, L., Pei, X., He, T., Shen, X., Wu, X., & Yang, H. (2018) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2018.29.e4 · Cited by 50
“A mutation of residue Q61 was only found in one patient in this cohort despite its status as a common mutation of KRAS in other human cancers [6].”
BackgroundInfluentialTesfaye, A. A., Kamgar, M., Azmi, A. S., & Philip, P. A. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1417844 · Cited by 49
Riemer, P., Sreekumar, A., Reinke, S., Rad, R., Schäfer, R., Sers, C., Bläker, H., Herrmann, B. G., & Morkel, M. (2014) · Oncogene · doi:10.1038/onc.2014.247 · Cited by 54
Cirstea, I. C., Gremer, L., Dvorsky, R., Zhang, S.-C., Piekorz, R. P., Zenker, M., & Ahmadian, M. R. (2013) · Human Molecular Genetics · doi:10.1093/hmg/dds426 · Cited by 45
Jolfayi, A. G., Kohansal, E., Ghasemi, S., Naderi, N., Hesami, M., MozafaryBazargany, M., Moghadam, M. H., Fazelifar, A. F., Maleki, M., & Kalayinia, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-56154-7 · Cited by 48
“Ras family small GTPases regulate growth and survival signaling 176 .”
BackgroundRamirez, C. F. A., Taranto, D., Ando‐Kuri, M., de Groot, M. H. P., Tsouri, E., Huang, Z., de Groot, D., Kluin, R. J. C., Kloosterman, D. J., Verheij, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46835-2 · Cited by 46
Oncogenes strike a balance between cellular growth and homeostasis
Qiu, B., & Simon, M. C. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.08.005 · Cited by 48
Carneiro, B. A., Kaplan, J. B., Altman, J. K., Giles, F. J., & Platanias, L. C. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1026510 · Cited by 45
JunD, not c-Jun, is the AP-1 transcription factor required for Ras-induced lung cancer
Ruiz, E. J., Lan, L., Diefenbacher, M. E., Riising, E. M., Costa, C. D., Chakraborty, A., Hoeck, J. D., Spencer‐Dene, B., Kelly, G. P., David, J., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.124985 · Cited by 44
Schulten, H.-J., Salama, S., Al-Ahmadi, A., Al-Mansouri, Z., Mirza, Z., Al‐Ghamdi, K., Al-Hamour, O. A., Huwait, E. A., Gari, M. A., Al-Qahtani, M. H., et al. (2013) · PubMed · Cited by 51
Small molecular inhibitors for KRAS-mutant cancers
Wu, X., Song, W., Cheng, C., Liu, Z., Li, X., Cui, Y., Gao, Y., & Li, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1223433 · Cited by 47
Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer
Qunaj, L., May, M. S., Neugut, A. I., & Herzberg, B. O. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1252516 · Cited by 48
Komatsu, N., Fujita, Y., Matsuda, M., & Aoki, K. (2015) · Oncogene · doi:10.1038/onc.2015.16 · Cited by 46
Kim, M., Chen, X., Chin, L. J., Paranjape, T., Speed, W. C., Kídd, K. K., Zhao, H., Weidhaas, J. B., & Slack, F. J. (2014) · Cell Cycle · doi:10.4161/cc.27941 · Cited by 45
Nullifying the CDKN2AB Locus Promotes Mutant K-ras Lung Tumorigenesis
Schuster, K., Venkateswaran, N., Rabellino, A., Girard, L., Peña-Llopis, S., & Scaglioni, P. P. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0620-t · Cited by 43
“KRAS is a small GTPase that regulates several oncogenic networks (5).”
BackgroundAmplification of mutated NRAS leading to congenital melanoma in neurocutaneous melanocytosis
Salgado, C. M., Basu, D., Nikiforova, M. N., Hamilton, R. L., Gehris, R. P., Jakacki, R. I., Panigrahy, A., Yatsenko, S. A., & Reyes‐Múgica, M. (2015) · Melanoma Research · doi:10.1097/cmr.0000000000000188 · Cited by 43
Prolyl 4-hydroxylase 2 promotes B-cell lymphoma progression via hydroxylation of Carabin
Jiang, W., Zhou, X., Li, Z., Liu, K., Wang, W., Tan, R., Cong, X., Shan, J., Zhan, Y., Cui, Z., et al. (2018) · Blood · doi:10.1182/blood-2017-07-794875 · Cited by 48
“Discussion The ras family of proto-oncogenes plays an essential role in tumorigenesis.(37,38) As downstream of BCR signaling pathway, gain-of-function mutations or dysregulation in the Ras/Erk pathway are frequently reported in different type of B lymphoma.”
BackgroundAbbott, J. R., Hodges, T. R., Daniels, R. N., Patel, P. A., Kennedy, J. P., Howes, J. E., Akan, D. T., Burns, M. C., Sai, J., Sobolik, T., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00360 · Cited by 40
Li, S., Hua, W., Wang, K., Gao, Y., Chen, S., Liu, W., Song, Y., Wu, X., Tu, J., Kang, L., et al. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.06.012 · Cited by 48
Regulators of the RAS-ERK pathway as therapeutic targets in thyroid cancer
Zaballos, M. A., Acuña-Ruíz, A., Morante, M., Crespo, P., & Santisteban, P. (2019) · Endocrine Related Cancer · doi:10.1530/erc-19-0098 · Cited by 44
Mercher, T., & Schwaller, J. (2019) · Frontiers in Pediatrics · doi:10.3389/fped.2019.00401 · Cited by 48
Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications
Vanni, I., Tanda, E. T., Dalmasso, B., Pastorino, L., Andreotti, V., Bruno, W., Boutros, A., Spagnolo, F., & Ghiorzo, P. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00172 · Cited by 47
Human PIF1 helicase supports DNA replication and cell growth under oncogenic-stress
Gagou, M. E., Ganesh, A. N., Phear, G. A., Robinson, D. A., Petermann, E., Cox, A., & Meuth, M. (2014) · Oncotarget · doi:10.18632/oncotarget.2501 · Cited by 44
“For our experimental system, we over-expressed the mutated form of the proto-oncogene RAS, H-RASG12V, commonly found in human tumours [29], in immortalized MRC5SV2 human fibroblasts.”
Drosten, M., Guerra, C. E., & Barbacid, M. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031542 · Cited by 43
“90%), colorectal carcinoma (45%), lung adenocarcinoma (LAC) (25%), and endometrial carcinoma (15%) with lower incidence rates in several other tumor types (Pylayeva-Gupta et al. 2011; Eser et al. 2014).”
BackgroundThe role of wild-type RAS in oncogenic RAS transformation
Sheffels, E., & Kortum, R. L. (2021) · Genes · doi:10.3390/genes12050662 · Cited by 42
Azman, M. S., Alard, E. L., Dodel, M., Capraro, F., Faraway, R., Dermit, M., Fan, W., Chakraborty, A., Ule, J., & Mardakheh, F. K. (2023) · The EMBO Journal · doi:10.15252/embj.2022110902 · Cited by 45
“…of these downstream kinase signaling pathways, which phosphorylate a plethora of cellular substrates, including a number of transcription factors, ultimately resulting in significant changes in the gene expression profile that promote various aspects of malignancy (Pylayeva-Gupta et al, 2011).”
BackgroundInvestigating the NRAS 5' UTR as a Target for Small Molecules
Balaratnam, S., Torrey, Z. R., Calabrese, D. R., Banco, M. T., Yazdani, K., Xiao, L., Fullenkamp, C. R., Seshadri, S., Holewinski, R. J., Andrésson, Þ., et al. (2022) · Cell chemical biology · doi:10.1016/j.chembiol.2023.05.004 · Cited by 44
Genetic pathways linking hemostasis and cancer
Garnier, D., Magnus, N., D’Asti, E., Hashemi, M., Meehan, B., Milsom, C., & Rak, J. W. (2012) · Thrombosis Research · doi:10.1016/s0049-3848(12)70012-9 · Cited by 47
“RAS genes undergo oncogenic mutations in a particularly large proportion (up to 30%) of human cancers, and their protein products are almost uniformly activated in tumour cells downstream of numerous growth factor and stimulatory pathways [1,115].”
BackgroundNussinov, R., Tsai, C.-J., Muratcioglu, S., Jang, H., Gursoy, A., & Keskin, O. (2015) · Expert Review of Proteomics · doi:10.1586/14789450.2015.1100079 · Cited by 42
“These are significant questions since in some cell types, the Raf/MEK/ERK (mitogen-activated protein kinase (MAPK)),[3–6] PI3K/ Akt [7,8] and RalGDS/Ras-like small GTPases (Ral) (RalGEF) [7,9] pathways that they activate oppose each other.”
Yamaguchi, M., Osuka, S., Weitzmann, M. N., El‐Rayes, B. F., Shoji, M., & Murata, T. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3409 · Cited by 43
“The observed frequency of K-ras brings about the consistent expression of irregular Ras protein that causes aberrant activation of cell proliferation, migration, invasion and survival pathways (1,10).”
BackgroundMethodSanz-Rodríguez, M., Gruart, A., Escudero‐Ramirez, J., de Castro, F., Delgado-Garcia, J. M., Wandosell, F. G., & Cubelos, B. (2018) · Journal of Neuroscience · doi:10.1523/jneurosci.3364-17.2018 · Cited by 44
“These membrane-anchored intracellular signal transducers that act through both PI3K/Akt and Erk1/2-MAPK pathways (Arimura and Kaibuchi, 2007) to influence various cell functions, including proliferation, differentiation, and cell survival (Karnoub and Weinberg, 2008; Pylayeva-Gupta et al., 2011).”
BackgroundSun, W., Wei, P., Tian, Y., Zou, W., Liu, J., & Zu, Y. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000495835 · Cited by 42
Song, M., Ou, F., Zemla, T., Hull, M. A., Shi, Q., Limburg, P. J., Alberts, S. R., Sinicrope, F. A., Giovannucci, E. L., Blarigan, E. L. V., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32113 · Cited by 46
“Distal colon 206 (46) 179 (42) 205 (47) 219 (51)”
Cancer Genetic Network Inference Using Gaussian Graphical Models
Zhao, H., & Duan, Z.-H. (2019) · Bioinformatics and Biology Insights · doi:10.1177/1177932219839402 · Cited by 55
CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic Targets
Kohlmeyer, J. L., Gordon, D. J., Tanas, M. R., Monga, V., Dodd, R. D., & Quelle, D. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21083018 · Cited by 43
RAS oncogenic activity predicts response to chemotherapy and outcome in lung adenocarcinoma
East, P., Kelly, G. P., Biswas, D., Marani, M., Hancock, D. C., Creasy, T. H., Sachsenmeier, K. F., Swanton, C., Downward, J., & Trécesson, S. D. C. (2022) · Nature Communications · doi:10.1038/s41467-022-33290-0 · Cited by 43
Sun, Q., Phan, J., Friberg, A. R., Camper, D. V., Olejniczak, E. T., & Fesik, S. W. (2014) · Journal of Biomolecular NMR · doi:10.1007/s10858-014-9849-8 · Cited by 41
“K-Ras is a highly validated cancer target (Pylayeva-Gupta et al. 2011).”
Howes, J. E., Akan, D. T., Burns, M. C., Rossanese, O. W., Waterson, A. G., & Fesik, S. W. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0666 · Cited by 42
“Hyperactivation of RAS signaling confers capabilities, known as the Hallmarks of Cancer (6) that cause the cell to become malignant (7).”
BackgroundLAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth
Erice, O., Narayanan, S., Feliu, I., Entrialgo‐Cadierno, R., Malinova, A., Vicentini, C., Guruceaga, E., Delfino, P., Trajkovic‐Arsic, M., Moreno, H., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0794 · Cited by 42
Igarashi, T., Mazevet, M., Yasuhara, T., Yano, K., Mochizuki, A., Nishino, M., Yoshida, T., Yoshida, Y., Takamatsu, N., Yoshimi, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40578-2 · Cited by 46
Down-Regulation of miR-4500 Promoted Non-Small Cell Lung Cancer Growth
Zhang, L., Qian, J., Qiang, Y., Huang, H., Wang, C., Li, D., & Xu, B. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000366329 · Cited by 41
Park, K., Oh, B., Lee, M.-H., Nam, K., Jin, H. R., Yang, H., Choi, J., Kim, S., & Lee, D. H. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.12.015 · Cited by 42
“KRAS is a member of the RAS family of oncogenes, a collection of small guanosine triphosphate (GTP)-binding proteins that integrate extracellular cues and activate intracellular signaling pathways to regulate cell proliferation, differentiation, and survival [1].”
BackgroundSur8/Shoc2 promotes cell motility and metastasis through activation of Ras-PI3K signaling
Kaduwal, S., Jeong, W.-J., Park, J.-C., Lee, K. H., Lee, Y.-M., Jeon, S.-H., Lim, Y.-B., Min, D. S., & Choi, K.-Y. (2015) · Oncotarget · doi:10.18632/oncotarget.5173 · Cited by 40
“In addition, oncogenic Ras-driven tumor malignancy is observed in one-third of all human cancers [35, 36], Ras has become a major target for the development of anti-cancer drugs.”
BackgroundAMKL chimeric transcription factors are potent inducers of leukemia
Dang, J., Nance, S. R., Ma, J., Cheng, J., Walsh, M. P., Vogel, P., Easton, J. B., Song, G., Rusch, M. A., Gedman, A. L., et al. (2017) · Leukemia · doi:10.1038/leu.2017.51 · Cited by 43
Gur, H. D., Loghavi, S., Garcia‐Manero, G., Routbort, M., Kanagal‐Shamanna, R., Quesada, A. E., Khogeer, H. A., Pierce, S. A., Medeiros, L. J., Kantarjian, H. M., et al. (2018) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001058 · Cited by 42
“146 Mann-Whitney U test Platelet count (×10(9)/L) 151 (14-488) 93 (2-1554) 0.”
RASSF1A Deficiency Enhances RAS-Driven Lung Tumorigenesis
Schmidt, M., Hobbing, K. R., Donninger, H., & Clark, G. J. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2466 · Cited by 44
“Activated RAS is thought to function primarily by binding and activating threemain types ofmitogenic effector proteins: the RAF kinases, PI-3 kinase, and the RALGEF family, to stimulate progrowth and survival pathways (4).”
Matheson, E. C., Thomas, H. D., Case, M. C., Blair, H. J., Jackson, R. K., Mašić, D., Veal, G. J., Halsey, C., Newell, D. R., Vormoor, J. H., et al. (2019) · Haematologica · doi:10.3324/haematol.2017.185975 · Cited by 43
Lin, T., Ren, Q., Zuo, W., Jia, R., Xie, L., Lin, R., Zhao, H., Chen, J., Yan, L., Wang, P., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1160-9 · Cited by 42
Wang, Z., Kim, U., Liu, J., Cheng, C., Wu, W., Guo, S., Feng, Y., Quinn, R. J., Hou, Y., & Bai, G. (2019) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-019-01962-4 · Cited by 42
KRAS: A Promising Therapeutic Target for Cancer Treatment
Wu, H.-Z., Xiao, J., Xiao, S., & Cheng, Y. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190905164144 · Cited by 43
Wang, H., Liu, C., Zhao, Y., Zhang, W., Xu, K., Li, D., Zhou, Y., Li, H., Xiao, G., Lü, B., et al. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.11.187 · Cited by 43
Chen, P. B., Fiaux, P. C., Zhang, K., Li, B., Kubo, N., Jiang, S., Hu, R., Rooholfada, E., Wu, S., Wang, M., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111630 · Cited by 36
Wang, X., Shu, G., Gao, C., Yang, Y., Xu, Q., & Tang, M. X. (2014) · Analytical Biochemistry · doi:10.1016/j.ab.2014.08.023 · Cited by 41
“K-ras is the most frequently mutated ras isoform, with an incidence of approximately 15% across all human tumor types [5,6].”
BackgroundZhang, L., Singh, R. R., Patel, K. P., Stingo, F. C., Routbort, M. J., You, M. J., Miranda, R. N., Garcia‐Manero, G., Kantarjian, H. M., Medeiros, L. J., et al. (2014) · American Journal of Hematology · doi:10.1002/ajh.23652 · Cited by 42
“They play a central role in cell signaling through dual activation of the RAS-RAF-MEK-MAPK-ERK (MAPK) pathway, an important regulator of cell proliferation, differentiation, and survival [9].”
BackgroundIdentification of a New Potent Inhibitor Targeting KRAS in Non-small Cell Lung Cancer Cells
Xie, C., Li, Y., Li, L.-L., Fan, X.-X., Wang, Y.-W., Wei, C.-L., Liu, L., Leung, E. L.-H., & Yao, X.-J. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00823 · Cited by 40
“KRAS plays an important role in normal cell development, such as proliferation and differentiation (Pylayeva-Gupta et al., 2011; Santarpia et al., 2012).”
BackgroundVasseur, R., Skrypek, N., Duchêne, B., Renaud, F., Martínez‐Maqueda, D., Vincent, A., Porchet, N., SEUNINGEN, I. V., & Jonckheere, N. (2015) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2015.10.014 · Cited by 43
Mito, J. K., Min, H. D., Ma, Y., Carter, J. E., Brigman, B. E., Dodd, L. G., Dankort, D. L., McMahon, M., & Kirsch, D. G. (2012) · The Journal of Pathology · doi:10.1002/path.4099 · Cited by 42
Liu, W., Yin, Y., Wang, J., Shi, B., Zhang, L., Qian, D., Li, C., Zhang, H., Wang, S., Zhu, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10162 · Cited by 42
Niida, A., Sasaki, S., Yonemori, K., Sameshima, T., Yaguchi, M., Asami, T., Sakamoto, K., & Kamaura, M. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.04.063 · Cited by 42
MYC and RAF: Key Effectors in Cellular Signaling and Major Drivers in Human Cancer
Stefan, E., & Bister, K. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_4 · Cited by 44
“Many external but also internal signals converge on the RAS isoforms to trigger a collection of non-redundant biological functions (Karnoub and Weinberg 2008; Pylayeva-Gupta et al. 2011; McCormick 2016).”
BackgroundExceptionally high-affinity Ras binders that remodel its effector domain
McGee, J. H., Shim, S. Y., Lee, S.-J., Swanson, P. K., Jiang, S. Y., Durney, M. A., & Verdine, G. L. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.816348 · Cited by 40
Akao, Y., Kumazaki, M., Shinohara, H., Sugito, N., Kuranaga, Y., Tsujino, T., Yoshikawa, Y., & Kitade, Y. (2018) · Cancer Science · doi:10.1111/cas.13559 · Cited by 40
“The 3 classical mammalian ras genes, K-ras, N-ras and H-ras, encode 21-Kd proteins that are members of the guanine nucleotide-binding protein superfamily.(1,2) The canonical properties of Ras are those of a small GTPase that normally cycles between a GTP-bound active and a GDP-bound inactive state.”
BackgroundIkeno, Y., Seo, S., Iwaisako, K., Yoh, T., Nakamoto, Y., Fuji, H., Taura, K., Okajima, H., Kaido, T., Sakaguchi, S., et al. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1475-x · Cited by 40
Oncogenic KRAS signaling activates mTORC1 through COUP‐TFII‐mediated lactate production
Byun, J., Park, M., Yun, J. W., Lee, J., Kim, J. S., Cho, S. J., Lee, Y. M., Lee, I., Choi, Y., & Park, K. (2019) · EMBO Reports · doi:10.15252/embr.201847451 · Cited by 40
“…glycolysis by controlling glycolytic signaling (such as that of PI3K/ AKT) as well as the expression of various glycolytic genes including GLUT1 [4,19], whereas COUP-TFII is involved in LDHA expression (data not shown); thereby, COUP-TFII overexpression in KRAS - silenced cells could not fully…”
Sasayama, Y., Hasegawa, M., Taguchi, E., Kubota, K., Kuboyama, T., Naoi, T., Yabuuchi, H., Shimai, N., Asano, M., Tokunaga, A., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.09.004 · Cited by 41
Topological and Functional Properties of the Small GTPases Protein Interaction Network
Delprato, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044882 · Cited by 43
Pancreatic Cancer from Molecular Pathways to Treatment Opinion
Karanikas, M., Esempidis, A., Chasan, Z. T. M., Deftereou, T.-E., Antonopoulou, M. I., Bozali, F., Amarantidis, K., & Man, Y.-G. (2016) · Journal of Cancer · doi:10.7150/jca.15419 · Cited by 47
“[64] Tipifarnib a farnesyl-transferase inhibitors failed to improve overall survival either as a single agent or in combination with gemcitabine in a phase III trial.[65, 66] Since it is difficult to target Ras directly, another solution would be to block targets downstream of KRAS, such as the protein kinase MEK.”
BackgroundLeung, E. L., Luo, L. X., Li, Y., Liu, Z., Li, L. L., Shi, D. F., Xie, Y., Huang, M., Lu, L. L., Duan, F. G., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32222 · Cited by 39
Kohal, R., Bisht, P., Gupta, G. D., & Verma, S. K. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.107095 · Cited by 40
Covalent Ras Dimerization on Membrane Surfaces through Photosensitized Oxidation
Chung, J. K., Lee, Y. K., Lam, H. Y. M., & Groves, J. T. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.5b12648 · Cited by 39
Schöpel, M., Jockers, K. F. G., Düppe, P. M., Autzen, J., Potheraveedu, V. N., Ince, S., Yip, K. T., Heumann, R., Herrmann, C., Scherkenbeck, J., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401291q · Cited by 38
González, R., Molina-Ruiz, F. J., Bárcena, J. A., Padilla, C. A., & Muntané, J. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7072 · Cited by 40
“Ras is strongly involved in oncogenic transformation evidenced by the high frequency of Ras mutations observed in cancer cells (159).”
RAS interaction with Sin1 is dispensable for mTORC2 assembly and activity
Castel, P., Dharmaiah, S., Sale, M. J., Messing, S. A. J., Rizzuto, G. A., Cuevas-Navarro, A., Cheng, A. S., Trnka, M. J., Urisman, A., Esposito, D., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2103261118 · Cited by 40
Autophagy Modulation and Cancer Combination Therapy: A Smart Approach in Cancer Therapy
Jeda, A. S., Ghabeshi, S., pour, Z. G. M., Jazaeri, E. O., Araiinejad, M., Sheikholeslami, F., Abdoli, M., Edalat, M., & Abdoli, A. (2022) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2022.100512 · Cited by 46
Gallardo, A., Molina, A., Asenjo, H. G., López-Onieva, L., Martorell‐Marugán, J., Espinosa-Martínez, M., Griñán‐Lisón, C., Álvarez-Pérez, J. C., Cara, F. E., Navarro-Marchal, S. A., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02375-x · Cited by 40
“In addition, constitutive KRAS signalling is a major oncogenic driver that can induce mesenchymalization of cancer cells [34].”
BackgroundEmerging role of the KRAS-PDK1 axis in pancreatic cancer
Ferro, R., & Falasca, M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i31.10752 · Cited by 46
Insights into K-Ras 4B regulation by post-translational lysine acetylation
Knyphausen, P., Lang, F., Baldus, L., Extra, A., & Lammers, M. (2016) · Biological Chemistry · doi:10.1515/hsz-2016-0118 · Cited by 41
Ruicci, K. M., Pinto, N. C., Khan, M. I., Yoo, J., Fung, K., MacNeil, S. D., Mymryk, J. S., Barrett, J. W., & Nichols, A. C. (2018) · Oral Oncology · doi:10.1016/j.oraloncology.2018.07.010 · Cited by 40
Intrinsic GTPase activity of K-RAS monitored by native mass spectrometry
Moghadamchargari, Z., Huddleston, J., Shirzadeh, M., Zheng, X., Clemmer, D. E., M. Raushel, F., Russell, D. H., & Laganowsky, A. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00532 · Cited by 38
Sequential oncogenic mutations influence cell competition
Kohashi, K., Mori, Y., Narumi, R., Kozawa, K., Kamasaki, T., Ishikawa, S., Kajita, M., Kobayashi, R., Tamori, Y., & Fujita, Y. (2021) · Current Biology · doi:10.1016/j.cub.2021.06.064 · Cited by 39
CPI-17 drives oncogenic Ras signaling in human melanomas via Ezrin-Radixin-Moesin family proteins
Riecken, L. B., Zoch, A., Wiehl, U., Reichert, S., Scholl, I., Cui, Y., Ziemer, M., Anderegg, U., Hagel, C., & Morrison, H. (2016) · Oncotarget · doi:10.18632/oncotarget.12919 · Cited by 38
“Aberrant Ras activity has strong oncogenic effects, causing several different forms of cancer [1-3].”
BackgroundPhosphorylation weakens but does not inhibit membrane binding and clustering of K-Ras4B
Zhang, S.-Y., Sperlich, B., Li, F.-Y., Al-Ayoubi, S., Chen, H.-X., Zhao, Y.-F., Li, Y.-M., Weise, K., Winter, R., & Chen, Y.-X. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00165 · Cited by 36
Grb2 and GRAP connect the B cell antigen receptor to Erk MAP kinase activation in human B cells
Vanshylla, K., Bartsch, C., Hitzing, C., Krümpelmann, L., Wienands, J., & Engels, N. (2018) · Scientific Reports · doi:10.1038/s41598-018-22544-x · Cited by 41
Osumi, H., Vecchione, L., Keilholz, U., Vollbrecht, C., Alig, A. H. S., von Einem, J. C., Stahler, A., Striefler, J. K., Kurreck, A., Kind, A. J., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.05.010 · Cited by 39
Therapeutic effect of curcumin in gastrointestinal cancers: A comprehensive review
Morshedi, K., Borran, S., Ebrahimi, M. S., khooy, M. J. M., Seyedi, Z. S., Amiri, A., Abbasi‐Kolli, M., Fallah, M., Khan, H. Z., Sahebkar, A., et al. (2021) · Phytotherapy Research · doi:10.1002/ptr.7119 · Cited by 38
Approaches to identifying synthetic lethal interactions in cancer.
Thompson, J. M., Nguyen, Q., Singh, M., & Razorenova, O. V. (2015) · PubMed · Cited by 50
A clinical perspective on the role of chronic inflammation in gastrointestinal cancer
Alguel, H., & Rasch, S. (2014) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s43457 · Cited by 40
Targeting cancer's metabolic co-dependencies: A landscape shaped by genotype and tissue context
Bi, J., Wu, S., Zhang, W., & Mischel, P. S. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.05.002 · Cited by 37
Discovery of Quinazolines That Activate SOS1-Mediated Nucleotide Exchange on RAS
Abbott, J. R., Patel, P. A., Howes, J. E., Akan, D. T., Kennedy, J. P., Burns, M. C., Browning, C. F., Sun, Q., Rossanese, O. W., Phan, J., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00296 · Cited by 39
Casar, B., Badrock, A. P., Jiménez, I., Arozarena, I., Colón‐Bolea, P., Lorenzo‐Martín, L. F., Ramirez, I. B.-R., Barriuso, J., Cappitelli, V., Donoghue, D. J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05941-8 · Cited by 42
Metadata
- Authors
- Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D.
- Affiliations
- New York University (US)
- ORCID
- Grabocka, Elda
- Venue
- Nature Reviews Cancer
- Published
- 2011-10-13
- Volume
- 11
- Issue
- 11
- Pages
- 761-774
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC3632399
- OpenAlex
- W1970527559
- Cited by
- 1,789
- References
- 239
- Citations by year
- 2026: 78 · 2025: 95 · 2024: 108 · 2023: 109 · 2022: 123 · 2021: 154 · 2020: 113 · 2019: 144 · 2018: 124 · 2017: 143 · 2016: 156 · 2015: 139 · 2014: 123 · 2013: 111 · 2012: 59
- FWCI
- 8.51
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Cancer Research Institute
- National Cancer Institute (R01CA055360, 1F32CA13922, CA 055360, R37CA055360, R56CA055360)
- National Institute of General Medical Sciences (R01GM078266, GM078266)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- oncogenic Ras, oncogenic Ras mutations, carcinogenesis, Ras isoforms, missense mutations, cell-autonomous effects, non-cell-autonomous effects, signaling pathways, cancer
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Humans, Neoplasm Metastasis, Genes, ras, Apoptosis, Mutation, Missense, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.